作者: Jacqueline Vuky , Richard Yu , Lawrence Schwartz , Robert J. Motzer
关键词: Anemia 、 Carcinoma 、 Surgery 、 Renal cell carcinoma 、 Liver function tests 、 Kidney disease 、 Gastroenterology 、 Kidney 、 Arsenic trioxide 、 Internal medicine 、 Chemotherapy 、 Medicine
摘要: Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial arsenic trioxide (As2O3). Eligible had bidimensionally measurable disease, Karnofsky performance status of at least 70%, life expectancy greater than three months, and no evidence brain metastases. Arsenic was given intravenously dose 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed grade elevation in liver function tests (36%), anemia (21%), insufficiency (14%), rash (7%), diarrhea (7%). Best response stable disease 3 one patient remaining study 8+ months At the schedule used this trial, did not achieve complete or partial carcinoma.